MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$23,206,372
EPS
-$2.77
Unit: Dollar
Subscribe for Financial Insights
Page 1
Annual
123
Page 1
Income Statement
2026-04-30
2025-04-30
Revenue
0
0
Research and development costs
391,301
438,416
Intangible asset impairment
1,549,427
0
General and administrative
4,912,985
3,939,446
Total operating expenses
6,853,713
4,377,862
Loss from operations
-6,853,713
-4,377,862
Loss on long term asset
-
0
Interest income
733,351
1,415,561
Gain on investment in preferred stock tnf
-
21,395,734
Dividend income
380,682
-
Change in fair value of investment tnf
-
5,063,950
Change in fair value of warrant liability
-4,746,135
10,446,000
Change in fair value of derivative liability
1,117,000
2,184,000
Change in fair value of warrant assets - tnf
-
-2,367,684
Change in fair value of convertible note receivable femasys
1,304,000
941,000
Change in fair value of warrant asset femasys
-2,581,000
-2,091,000
Change in fair value of investment qcls
-7,732,000
-
Change in fair value of warrant assets qcls
-1,379,000
-
Gain on related party investment qcls
2,089,000
-
Gain on legal settlement re-fair value of warrants
106,000
-
Issuance costs series c convertible preferred stock and warrants
-1,234,553
-
Unrealized gain (loss) on marketable securities
-412,306
66,316
Loss on legal settlement
0
-2,019,000
Loss on issuance of series c preferred stock
-215,000
-
Other expense, net
-980
-965
Total other income (expense), net
-12,570,941
35,033,912
Income tax benefit (expense)
0
0
Net income (loss)
-19,424,654
30,656,050
Preferred stock dividends
278,496
1,129,759
Undistributed income to series b convertible preferred stock
0
2,970,780
Preferred stock accretion
3,503,222
3,193,404
Net income (loss) attributable to common stockholders
-23,206,372
23,362,107
Basic EPS
-2.77
3.19
Diluted EPS
-2.77
3.19
Basic Average Shares
8,378,291
7,329,596
Diluted Average Shares
8,378,291
7,329,596
Page 1
Unit: Dollar.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net income (loss)
attributable to common...
-$23,206,372
(-199.33%↓ Y/Y)
Net income (loss)
-$19,424,654
(-163.36%↓ Y/Y)
Preferred stock accretion
$3,503,222
(9.70%↑ Y/Y)
Preferred stock dividends
$278,496
(-75.35%↓ Y/Y)
Total other income
(expense), net
-$12,570,941
(-135.88%↓ Y/Y)
Loss from operations
-$6,853,713
(-56.55%↓ Y/Y)
Gain on related party
investment qcls
$2,089,000
Change in fair value of
convertible note receivable ...
$1,304,000
(38.58%↑ Y/Y)
Change in fair value of
derivative liability
$1,117,000
(-48.86%↓ Y/Y)
Interest income
$733,351
(-48.19%↓ Y/Y)
Dividend income
$380,682
Gain on legal
settlement re-fair value of...
$106,000
Change in fair value of
investment qcls
-$7,732,000
Change in fair value of
warrant liability
-$4,746,135
(-145.43%↓ Y/Y)
Change in fair value of
warrant asset femasys
-$2,581,000
(-23.43%↓ Y/Y)
Total operating
expenses
$6,853,713
(56.55%↑ Y/Y)
Change in fair value of
warrant assets qcls
-$1,379,000
Issuance costs series c
convertible preferred stock...
-$1,234,553
Unrealized gain (loss) on
marketable securities
-$412,306
(-721.73%↓ Y/Y)
Loss on issuance of
series c preferred...
-$215,000
Other expense, net
-$980
(-1.55%↓ Y/Y)
General and
administrative
$4,912,985
(24.71%↑ Y/Y)
Intangible asset
impairment
$1,549,427
Research and development
costs
$391,301
(-10.75%↓ Y/Y)
Buy us a coffee
PharmaCyte Biotech, Inc. (PMCB)
PharmaCyte Biotech, Inc. (PMCB)